Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19.
作者信息
Razonable Raymund R, Chen Peter
机构信息
Division of Public Health, Infectious Diseases and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN, United States.
Department of Medicine, Women's Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
出版信息
Front Immunol. 2022 May 31;13:938069. doi: 10.3389/fimmu.2022.938069. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19.社论：中和抗体在新型冠状病毒肺炎预防与治疗中的应用
Front Immunol. 2022 May 31;13:938069. doi: 10.3389/fimmu.2022.938069. eCollection 2022.
2
A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern and .一种基于双荧光的方法，用于鉴定针对 SARS-CoV-2 关切变异株和 的中和抗体。
J Virol. 2021 Oct 27;95(22):e0112621. doi: 10.1128/JVI.01126-21. Epub 2021 Sep 8.
3
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.康复者中 SARS-CoV-2 感染的性别差异和中和抗体持久性。
mSphere. 2021 Aug 25;6(4):e0027521. doi: 10.1128/mSphere.00275-21.
4
Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.新冠病毒感染 14 个月后 COVID-19 恢复期患者结合抗体和中和抗体的动态分析。
Front Immunol. 2021 Nov 26;12:793953. doi: 10.3389/fimmu.2021.793953. eCollection 2021.
5
SARS-CoV-2 Neutralizing Antibodies for COVID-19 Prevention and Treatment.用于 COVID-19 预防和治疗的 SARS-CoV-2 中和抗体。
Annu Rev Med. 2022 Jan 27;73:1-16. doi: 10.1146/annurev-med-042420-113838. Epub 2021 Aug 24.
6
Neutralizing Response Against SARS-CoV-2 Variants 8 Months After BNT162b2 Vaccination in Naive and COVID-19-Convalescent Individuals.接种 BNT162b2 疫苗 8 个月后对 SARS-CoV-2 变异体的中和反应在未感染和 COVID-19 恢复期个体中。
J Infect Dis. 2022 Jun 1;225(11):1905-1908. doi: 10.1093/infdis/jiab634.
7
Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.两种不同检测方法显示轻度 COVID-19 恢复期患者血清中和抗 SARS-CoV-2 S 抗体水平较低。
Cell Mol Immunol. 2021 Apr;18(4):936-944. doi: 10.1038/s41423-020-00573-9. Epub 2020 Nov 2.
8
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.靶向刺突受体结合域的中和单克隆抗体赋予叙利亚仓鼠免受 SARS-CoV-2 感染的 Fc 受体非依赖性保护。
mBio. 2021 Oct 26;12(5):e0239521. doi: 10.1128/mBio.02395-21. Epub 2021 Sep 14.
9
Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.用于检测 COVID-19 恢复期血浆中 SARS-CoV-2 特异性 IgG 的多重冠状病毒抗原阵列的评估。
J Immunol Methods. 2021 Oct;497:113104. doi: 10.1016/j.jim.2021.113104. Epub 2021 Jul 22.
10
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.接种灭活疫苗后 160 天内血清抗 SARS-CoV-2 抗体的反应和持续时间。
Front Immunol. 2021 Dec 23;12:786554. doi: 10.3389/fimmu.2021.786554. eCollection 2021.
引用本文的文献
1
Weak Value Amplification Based Optical Sensor for High Throughput Real-Time Immunoassay of SARS-CoV-2 Spike Protein.基于弱值放大的光学传感器用于 SARS-CoV-2 刺突蛋白高通量实时免疫分析。
Biosensors (Basel). 2024 Jul 8;14(7):332. doi: 10.3390/bios14070332.
2
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies.基于SARS-CoV-2中和抗体的治疗机制与应用综述
Front Microbiol. 2023 Mar 16;14:1122868. doi: 10.3389/fmicb.2023.1122868. eCollection 2023.
Zotero 插件